TABLE 1.
HIV-1 RT substitutions observed in dose escalation selection experiments with HIV-1 subtypes A, B, and Ca
| HIV-1 subtype | Serum type | Passage no. | Amino acid substitutions (no. of replicate experiments observed) |
|
|---|---|---|---|---|
| Commonb | Otherc | |||
| A | FBS | 6 | None observed | None observed |
| B | FBS | 4 | M184I (3), M184VI (2), M184MI (2), M184V (1) | E36EK (1) |
| 11 | M184I (6), M184V (2), | K166KRe (1) | ||
| 38 | M184MVI (3), M184V (3), M184I (1), M184MI (1), V90VI (1), C162CY (1) | K166KRe (1), G196GR (1), M41L (1), A114S (1), A400T (1) | ||
| C | FBS | 12 | None observed | None observed |
| Ad | NHS | 36 | M184I (6), M184VI (2) | None observed |
| B | NHS | 4 | None observed | P313PTe (1) |
| 25 | M184MV (1), M184I (1) | H221HYe (1) | ||
| 34 | M184V (3), M184MV (1), M184VI (4), V90VI (1) | E36ED (1), A158AT (1), H221Ye (1), P313PTe (1) | ||
| C | NHS | 36 | M184I (5), M184VI (3), V90VI (1) | L74LI (1), V75VA (1) |
FBS, fetal bovine serum; HIV-1, human immunodeficiency virus type 1; ISL, islatravir or MK-8591; NHS, normal human serum; RT, reverse transcriptase.
Common substitutions are those observed in ≥2 replicate experiments out of 8 for each HIV-1 subtype/serum combination.
Other substitutions are those observed in multiples wells within a single-replicate experiment.
C162CY was only detected in 1 replicate experiment from this experiment but was also observed in 2 of 16 replicates from a separate experiment (data not published).
eSubstitutions at K166, H221, and P313 were each observed at multiple passages in the same replicate experiment and are not considered common.